We've found
184,457
clinical trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Imaging of Solid Gastrointestinal Tumors Clinical Trial
A Phase I Study of MLN6907 in Patients With Metastatic Colorectal
Status: Enrolling,
Phase
I
Updated: 10/6/2015
Click here to add this to my saved trials
Carotid Stenosis Clinical Trial
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Carotid Stenosis Clinical Trial
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Carotid Stenosis Clinical Trial
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Carotid Stenosis Clinical Trial
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Carotid Stenosis Clinical Trial
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials
Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials
Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials
Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials
Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials
Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials
Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials
Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials
Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials
Differentiated Thyroid Cancer Clinical Trial
An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 3/15/2016
Click here to add this to my saved trials
Differentiated Thyroid Cancer Clinical Trial
An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 3/15/2016
Click here to add this to my saved trials
Breast Cancer Clinical Trial
A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Head and Neck Squamous Cell Cancer Clinical Trial
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials
Head and Neck Squamous Cell Cancer Clinical Trial
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials
Head and Neck Squamous Cell Cancer Clinical Trial
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials
Head and Neck Squamous Cell Cancer Clinical Trial
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials
Head and Neck Squamous Cell Cancer Clinical Trial
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials
Head and Neck Squamous Cell Cancer Clinical Trial
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials
Head and Neck Squamous Cell Cancer Clinical Trial
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials
Head and Neck Squamous Cell Cancer Clinical Trial
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials
Head and Neck Squamous Cell Cancer Clinical Trial
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials
Head and Neck Squamous Cell Carcinoma HNSCC Clinical Trial
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Status: Enrolling,
Phase
II
Updated: 9/23/2015
Click here to add this to my saved trials
Head and Neck Squamous Cell Carcinoma HNSCC Clinical Trial
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Status: Enrolling,
Phase
II
Updated: 9/23/2015
Click here to add this to my saved trials
Head and Neck Squamous Cell Carcinoma HNSCC Clinical Trial
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Status: Enrolling,
Phase
II
Updated: 9/23/2015
Click here to add this to my saved trials
Head and Neck Squamous Cell Carcinoma HNSCC Clinical Trial
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Status: Enrolling,
Phase
II
Updated: 9/23/2015
Click here to add this to my saved trials
Head and Neck Squamous Cell Carcinoma HNSCC Clinical Trial
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Status: Enrolling,
Phase
II
Updated: 9/23/2015
Click here to add this to my saved trials
Head and Neck Squamous Cell Carcinoma HNSCC Clinical Trial
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Status: Enrolling,
Phase
II
Updated: 9/23/2015
Click here to add this to my saved trials
Clostridium Difficile Infection Clinical Trial
FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI
Status: Enrolling,
Phase
II
Updated: 3/22/2016
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Status: Enrolling,
Phase
III
Updated: 9/23/2015
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Status: Enrolling,
Phase
III
Updated: 9/23/2015
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Status: Enrolling,
Phase
III
Updated: 9/23/2015
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Status: Enrolling,
Phase
III
Updated: 9/23/2015
Click here to add this to my saved trials
Oncology Clinical Trial
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
We've found
184,457
clinical trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Imaging of Solid Gastrointestinal Tumors Clinical Trial
Updated: 10/6/2015
A Phase I Study of MLN6907 in Patients With Metastatic Colorectal
Status: Enrolling,
Phase
I
Updated: 10/6/2015
Click here to add this to my saved trials
Carotid Stenosis Clinical Trial
Updated: 12/31/1969
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Carotid Stenosis Clinical Trial
Updated: 12/31/1969
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Carotid Stenosis Clinical Trial
Updated: 12/31/1969
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Carotid Stenosis Clinical Trial
Updated: 12/31/1969
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Carotid Stenosis Clinical Trial
Updated: 12/31/1969
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
Updated: 3/30/2016
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials
Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
Updated: 3/30/2016
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials
Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
Updated: 3/30/2016
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials
Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
Updated: 3/30/2016
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials
Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
Updated: 3/30/2016
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials
Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
Updated: 3/30/2016
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials
Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
Updated: 3/30/2016
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials
Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
Updated: 3/30/2016
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials
Chronic Kidney Disease, Secondary Hyperparathyroidism Clinical Trial
Updated: 3/30/2016
A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis
Status: Enrolling,
Phase
III
Updated: 3/30/2016
Click here to add this to my saved trials
Differentiated Thyroid Cancer Clinical Trial
Updated: 3/15/2016
An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 3/15/2016
Click here to add this to my saved trials
Differentiated Thyroid Cancer Clinical Trial
Updated: 3/15/2016
An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 3/15/2016
Click here to add this to my saved trials
Breast Cancer Clinical Trial
Updated: 12/31/1969
A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Head and Neck Squamous Cell Cancer Clinical Trial
Updated: 4/7/2016
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials
Head and Neck Squamous Cell Cancer Clinical Trial
Updated: 4/7/2016
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials
Head and Neck Squamous Cell Cancer Clinical Trial
Updated: 4/7/2016
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials
Head and Neck Squamous Cell Cancer Clinical Trial
Updated: 4/7/2016
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials
Head and Neck Squamous Cell Cancer Clinical Trial
Updated: 4/7/2016
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials
Head and Neck Squamous Cell Cancer Clinical Trial
Updated: 4/7/2016
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials
Head and Neck Squamous Cell Cancer Clinical Trial
Updated: 4/7/2016
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials
Head and Neck Squamous Cell Cancer Clinical Trial
Updated: 4/7/2016
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials
Head and Neck Squamous Cell Cancer Clinical Trial
Updated: 4/7/2016
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials
Head and Neck Squamous Cell Carcinoma HNSCC Clinical Trial
Updated: 9/23/2015
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Status: Enrolling,
Phase
II
Updated: 9/23/2015
Click here to add this to my saved trials
Head and Neck Squamous Cell Carcinoma HNSCC Clinical Trial
Updated: 9/23/2015
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Status: Enrolling,
Phase
II
Updated: 9/23/2015
Click here to add this to my saved trials
Head and Neck Squamous Cell Carcinoma HNSCC Clinical Trial
Updated: 9/23/2015
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Status: Enrolling,
Phase
II
Updated: 9/23/2015
Click here to add this to my saved trials
Head and Neck Squamous Cell Carcinoma HNSCC Clinical Trial
Updated: 9/23/2015
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Status: Enrolling,
Phase
II
Updated: 9/23/2015
Click here to add this to my saved trials
Head and Neck Squamous Cell Carcinoma HNSCC Clinical Trial
Updated: 9/23/2015
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Status: Enrolling,
Phase
II
Updated: 9/23/2015
Click here to add this to my saved trials
Head and Neck Squamous Cell Carcinoma HNSCC Clinical Trial
Updated: 9/23/2015
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Status: Enrolling,
Phase
II
Updated: 9/23/2015
Click here to add this to my saved trials
Clostridium Difficile Infection Clinical Trial
Updated: 3/22/2016
FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI
Status: Enrolling,
Phase
II
Updated: 3/22/2016
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Updated: 9/23/2015
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Status: Enrolling,
Phase
III
Updated: 9/23/2015
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Updated: 9/23/2015
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Status: Enrolling,
Phase
III
Updated: 9/23/2015
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Updated: 9/23/2015
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Status: Enrolling,
Phase
III
Updated: 9/23/2015
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Updated: 9/23/2015
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Status: Enrolling,
Phase
III
Updated: 9/23/2015
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials